XEN45植入物两年疗效与安全性数据:回顾性分析
该回顾性非对照审计纳入2015年6月至2017年5月在英国国家健康服务体系内接受XEN45手术的151眼,随访24个月。结果显示平均眼压从基线22.1±6.5 mmHg降至12个月15.4±5.9 mmHg和24个月14.5±3.3 mmHg(p<0.001),平均降眼压药物从基线2.77±1.1种降至12个月0.3±0.7种和24个月0.5±1.0种(p<0.001)。24个月时25%患者失败,37.7%需针刺,非白种人与较高失败率相关,未记录显著不良事件。
要点
- XEN45术后24个月平均眼压从22.1 mmHg降至14.5 mmHg,降眼压药物从2.77种降至0.5种。
- 24个月时25%患者失败,37.7%需针刺,非白种人与较高失败率相关。
- 未记录显著不良事件,但需告知患者失败率及可能需滤过泡修正和用药。
核心结论
- XEN45在24个月随访中是可行、有效且安全的手术。
- 患者应被告知失败率以及可能需滤过泡修正和用药。
研究设计与样本
- 回顾性非对照审计,纳入2015年6月至2017年5月在英国国家健康服务体系内接受XEN45手术的患者记录,共151眼。
主要发现
- 主要诊断为原发性开角型青光眼(84.1%)、闭角型青光眼(8.6%)和难治性青光眼(7.3%)。
- 单独手术占62.3%,联合白内障手术(phaco-XEN)占37.7%。
- 平均眼压基线22.1±6.5 mmHg,12个月15.4±5.9 mmHg,24个月14.5±3.3 mmHg(p<0.001)。
- 平均降眼压药物基线2.77±1.1种,12个月0.3±0.7种,24个月0.5±1.0种(p<0.001)。
- 24个月时25%患者失败,37.7%需针刺,非白种人与较高失败率相关,未记录显著不良事件。
关键数值与推荐
- 失败定义为需进一步手术或移除XEN。
- 成功定义为眼压降低20%且无需额外青光眼药物,或减少降眼压药物且基线眼压未升高。
临床怎么用
- XEN45可作为青光眼手术选择,术后24个月能有效降低眼压和药物负担。
- 术前应告知患者24个月失败率约25%、针刺率约37.7%以及可能需滤过泡修正和用药。
- 非白种人患者失败率较高,需加强术后监测。
局限性
- 回顾性非对照审计设计。
- 单中心国家健康服务体系设置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To report efficacy and safety measures for XEN45 in a National Health Service setting after 24-month follow-up. METHODS: This is a retrospective, non-comparative audit of records of patients who underwent XEN45 procedure between June 2015 and May 2017. The main outcome measures were intraocular pressure (IOP) reduction and number of antihypertensive medications at each timepoint. Failure was defined as requiring further surgery or removal of XEN. Success was defined as 20% reduction of IOP without additional glaucoma medications or reduction in antihypertensive medications without increase in baseline IOP. Needling rates were assessed and subgroup analysis was performed. RESULTS: A total of 151 eyes were included in the study. The main diagnoses were primary open angle glaucoma (84.1%), angle closure glaucoma (8.6%) and refractory glaucoma (7.3%). Stand-alone procedure was performed in 62.3% and combined phaco-XEN was done in 37.7%. The mean IOP at baseline was 22.1±6.5 mm Hg, and the mean IOP at 12 and 24 months was 15.4±5.9 mm Hg and 14.5±3.3 mm Hg, respectively (p<0.001). The mean number of medications was 2.77±1.1 at baseline, and 0.3±0.7 and 0.5±1.0 medications at 12 and 24 months, respectively (p<0.001). 25% of patients failed at the 24-month timepoint. Needling was required in 37.7% of patients at 24 months. Non-Caucasian ethnicity was found to be related to higher failure rate. No significant adverse events were noted. CONCLUSION: XEN45 is a viable, effective and safe procedure after 2 years of follow-up. Patients should be advised regarding failure rate as well as possible need for bleb revisions and medication use.
引用
- Gabbay IE, Allen F, Morley C, et al. Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis. Br J Ophthalmol. 2019. PMID: 31727624. doi:10.1136/bjophthalmol-2019-313870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。